Q&A Genmab 2021-11-26

	26/11 15:11 af Jan Van de Winkel	I think JnJ is in a state of change with the CEO leaving in January and the CSO replaced in the coming months. We know the new CEO very well and are very familiar with the R&D organization of JnJ, which increasingly product candidates originating from Genmab's innovation towards the market. We are thus excited about this new phase for JnJ and look forward to continue our productive alliance in the coming years.
	26/11 15:11 af Darvin	Jan you have previously talked about infectious pathogens. Does Genmab have concrete and current plans to go into infectious diseases? If this is the case, it will be alone or could it be in collaboration with e.g. Biontech?
	26/11 15:13 af Jan Van de Winkel	Genmab is already testing some of its antibody technologies in disease areas outside of cancer including infectious diseases. The focus of the company will continue to be centered around treatment of cancer, albeit that Genmab's technology platforms may well be used way more broadly by partners.
	26/11 15:13 af Helge Larsen/PI-redaktør	And now to the last question
	26/11 15:14 af Jan Van de Winkel	We have never been in a stronger position than now with a fantastic team, a worldclass differentiated pipeline and a strong cash position..
	26/11 15:17 af Jan Van de Winkel	We can't wait to start 2022 where a lot of focus will be centered around epcoritamab and we hope to progress at least on of our programs into late stage clinical development and perhaps move one or more programs into expansion phases, on top of bringing one or more new molecules into the clinic. We are fully focussed on maximising the potential of the next potential winners and given our track record of successful product development, we feel that we will need a robust cash position..
	26/11 15:17 af Jan Van de Winkel	to maximise the impact on patients. Exciting times!
	26/11 15:18 af Helge Larsen/PI-redaktør	Thank you for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q4.
	26/11 15:18 af Jan Van de Winkel	Thank you for another exciting session. Stay safe, keep optimistic and have a wonderful weekend.
	26/11 15:20 af Helge Larsen/PI-redaktør	This session has ended.